TR BioSurgical To Present New Glaucoma Device Data At ACVO

Main Category: Veterinary
Article Date: 25 Sep 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


TR BioSurgical, LLC has been selected to present data concerning their proprietary glaucoma device, TR-ClarifEYE, at the American College of Veterinary Ophthalmologist's (ACVO) annual conference. Glaucoma affects a large percentage of dogs and has devastating consequences including pain and blindness. TR-ClarifEYE, made of a unique biomaterial, proposes to offer improved biocompatibility compared to current products and provide a much needed long-term solution for thousands of dogs each year which develop glaucoma.

Dr. Craig Woods, CEO of TR BioSurgical, LLC, stated, "We are excited to present our interim data at this year's veterinary ophthalmology meeting. Our team has developed a device with remarkable properties to enhance tissue integration and long term performance. We are very encouraged by the results and intend on establishing a limited global treatment network in the coming months, providing veterinarians access to the implant."

About Canine Glaucoma

Glaucoma is one of the most common causes of blindness in dogs and humans. Glaucoma is associated with an increase in pressure within the eye, referred to as intraocular pressure (IOP). Increased IOP causes pain and damage to sensitive tissues within the eye, resulting in a progressive loss of vision. Despite a number of surgical and medical options, canine glaucoma is still considered a disease with limited long term management options.

About TR ClarifEYE

TR ClarifEYE is a medical device consisting of medical grade silicone substrate that has been converted into the Sphere Templated Angiogenic Regeneration (STAR) Material by Healionics Corporation This unique process creates a precise pore structure that enhances healing and reduces fibrosis, an effect that proposes to permit long term filtration.

About TR BioSurgical, LLC

TR BioSurgical, LLC, founded in May 2007, is a rapidly growing veterinary biomedical development company located in Chandler, Arizona. The company was founded by veterinarians and business professionals and is developing a range of medical devices for veterinary use. For more information about TR BioSurgical, please visit http://www.trbio.com/.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading provider of tissue regeneration and device biointegration solutions to healthcare manufacturers. Their flagship STAR - Sphere Templated Angiogenic Regeneration - biomaterial scaffold is a next generation solution for improving the performance of implanted medical devices. Healionics Corporation is headquartered in Redmond, Washington.

Healionics Corporation

Article adapted by Medical News Today from original press release.
Visit our veterinary section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
TR BioSurgical, LLC. "TR BioSurgical To Present New Glaucoma Device Data At ACVO." Medical News Today. MediLexicon, Intl., 25 Sep. 2008. Web.
8 Feb. 2012. <http://www.medicalnewstoday.com/releases/122916.php>

APA
TR BioSurgical, LLC. (2008, September 25). "TR BioSurgical To Present New Glaucoma Device Data At ACVO." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/122916.php.

Please note: If no author information is provided, the source is cited instead.


Veterinary

Most Popular Articles



Follow Our Veterinary News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Veterinary Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »